17 results for "Meta-analysis: What did research on Serotonin find in February 2026?"

Delayed psilocybin treatment after repeated mild traumatic brain injury recovers chronic behavioural deficits, reduces microglial density, and enhances hippocampal neurogenesis in rats

Research Square February 23, 2026 Sandy R Shultz, Josh Allen, Grace O'Regan et al.

Abstract Repeated mild traumatic brain injury (RmTBI) can produce lasting cognitive, emotional, and social deficits (e.g., persistent post-concussion symptoms; PPCS). Despite the prevalence of RmTBI in sports, military, and domestic violence settings, effective treatments to alleviate the neurological consequences of RmTBI remain limited. Psilocybin, a serotonergic psychedelic, can enhance...

DOI: 10.21203/rs.3.rs-8555503/v1 Psilocybin Neuroplasticity Serotonergic Neurogenesis +12

Opioid Receptors in Psychedelia: Indirect Serotonergic Modulation of Direct KOR Activation by Salvinorin A

Biomedicines February 21, 2026 Maximiliano Ganado, Carmen Rubio, Javier Pérez-villavicencio et al.

The neuropharmacology of psychedelics has traditionally focused on serotonergic mechanisms, particularly 5-HT2A receptor activation. However, this paradigm incompletely explains the diversity of neurobiological and therapeutic effects observed across psychedelic compounds. Non-classical psychedelics such as salvinorin A, the primary active constituent of Salvia divinorum, challenge this...

DOI: 10.3390/biomedicines14020476 Serotonergic Neuropharmacology Dopaminergic Κ-opioid receptor +8

Predicting drug–drug interactions between ayahuasca alkaloids and SSRIs using physiologically based pharmacokinetic modeling

Frontiers in Molecular Biosciences February 18, 2026 Gabriella de Souza Gomes Ribeiro, Beatriz Aparecida Passos Bismara Paranhos, Fabiane Dörr et al. 1 citation

The findings suggest a clinically relevant interaction between ayahuasca and SSRIs, as even modest increases in DMT exposure may intensify serotonergic effects in individuals receiving antidepressant therapy. This study provides a mechanistic and quantitative framework for assessing interaction risks between ayahuasca alkaloids and SSRIs, supporting clinical decision-making and harm-reduction...

DOI: 10.3389/fmolb.2026.1768402 Ayahuasca Serotonergic Paroxetine Pharmacology +14

MDMA-Assisted Therapy for PTSD: Neuroplastic Change or Psychotherapeutic Catalyst?

Translation The University of Toledo Journal of Medical Sciences February 17, 2026 Amy Hooper, Evelyn K. Lambe

MDMA-assisted psychotherapy has emerged as a promising treatment for post-traumatic stress disorder (PTSD), particularly in individuals unresponsive to conventional interventions such as SSRIs and trauma-focused cognitive behavioral therapy. As recent clinical trials report durable symptom remission, ongoing debate surrounds the mechanisms underlying its therapeutic effects. This review...

DOI: 10.46570/utjms-2026-1674 MDMA Serotonergic Neuroplasticity Amygdala +8

Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathway

Neuropsychopharmacology February 13, 2026 Fabrizio Ascone, Valeria Buzzelli, Francesca Mottarlini et al. 2 citations

Fragile X Syndrome (FXS) is the most common inherited intellectual disability and a leading monogenic cause of autism spectrum disorder (ASD). As a synaptic disorder, FXS involves the loss of Fragile X messenger ribonucleoprotein 1 (FMRP), leading to abnormal dendrite development and immature dendritic spines. Serotonergic signaling, essential for neuronal development and circuit remodeling,...

DOI: 10.1038/s41386-026-02361-x Full text Serotonergic Psilocybin Synaptic plasticity Neuroplasticity +5

Binding pose depth modulates photoswitchable ligands’ efficacy at the 5-HT2A receptor

Communications Chemistry February 12, 2026 Verena Weber, Giacomo Salvadori, Federico Natale et al.

Abstract Photoswitchable ligands enable reversible control of receptor signaling through light-induced cis – trans isomerization, yet predicting how subtle structural modifications affect efficacy remains challenging. Here, we use molecular dynamics simulations to investigate two azobenzene-based human 5–HT 2A receptor ligands differing only by a methoxy substituent position ( para – vs meta...

DOI: 10.1038/s42004-026-01936-5 Full text Moiety Steric effects G protein-coupled receptor Ligand biochemistry +16

Correction: The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice

Molecular Psychiatry February 12, 2026 Sixtine Fleury, Katherine M. Nautiyal correction

should have read "Overall, our research implicates the 5-HT1BR, a nonhallucinogenic serotonin receptor, as a potential mediator of the behavioral and neural effects of psilocybin in mice."The final sentence of the Introduction should have read "Our findings suggest that the 5-HT1BR influences brain-wide neural changes following psilocybin administration and may contribute to its enduring...

DOI: 10.1038/s41380-026-03488-5 Full text Psilocybin Serotonergic Serotonin antagonists Hallucinogen +5

The effects of acute and repeated adolescent MDMA exposure on behavior, cognition, and the monoamine neurotransmitter systems: A review of human and pre-clinical research

Behavioural Brain Research February 10, 2026 Kristin A. Felsch, Jessica A. Siegel

3,4-methylenedioxymethamphetamine (MDMA) is a psychomotor stimulant drug. While much research has examined the effects of MDMA in adults, relatively little research has examined the effects in adolescents. Adolescence is a unique period of brain development, and the effects of MDMA may differ in adolescents compared to adults. In this review, we summarize the literature on the effects of acute...

DOI: 10.1016/j.bbr.2026.116098 MDMA Serotonin Ecstasy Serotonergic +10

N,N-dimethyltryptamine (DMT) is neither formed nor retained in serotonin terminals in the rat brain.

Open Access CRIS of the University of Bern February 9, 2026 Mikael Palner, Elisabeth Kolesnik, Christina Baun et al.

Mammalian brain may contain an endogenous pool of the psychedelic substance N,N-dimethyltryptamine (DMT), which may act as a co-transmitter with serotonin (5-HT). We tested the joint hypotheses. We tested the joint hypotheses that endogenous DMT would accumulate in rat brain after inhibiting monoamine oxidase with pargyline, whereas its acidic metabolite 3-indoleacetic acid (3-IAA) would...

DOI: 10.48620/94763 Serotonin Serotonergic Endogeny Pargyline +17

N,N-dimethyltryptamine (DMT) is neither formed nor retained in serotonin terminals in the rat brain

Neuropharmacology February 9, 2026 Mikael Palner, Elisabeth Kolesnik, Christina Baun et al.

Mammalian brain may contain an endogenous pool of the psychedelic substance N,N-dimethyltryptamine (DMT), which may act as a co-transmitter with serotonin (5-HT). We tested the joint hypotheses. We tested the joint hypotheses that endogenous DMT would accumulate in rat brain after inhibiting monoamine oxidase with pargyline, whereas its acidic metabolite 3-indoleacetic acid (3-IAA) would...

DOI: 10.1016/j.neuropharm.2026.110874 Full text Serotonin Harmine Endogeny Pargyline +16

Neurotransmitter Mechanisms of Ketamine and Ketamine–Magnesium Sulfate-Induced Hypothermia: Evidence for Serotonergic and Adrenergic Involvement Without GABAA Contributions

Brain Sciences February 4, 2026 Katarina Savić Vujović, Sonja Vučković, Lara Samardžić et al.

Background: Ketamine and magnesium sulfate are commonly used perioperatively to prevent shivering, a frequent and clinically relevant complication of spinal and general anesthesia. Although their hypothermic effects are well documented, the neurotransmitter mechanisms underlying these effects remain insufficiently understood. This study examines whether serotonergic, adrenergic (α2), and...

DOI: 10.3390/brainsci16020189 Serotonergic Ketamine Methysergide Bicuculline +15

Computational Analysis of Psilocybin Effects on Three-Choice Touchscreen Reversal Learning in Rats: A Pilot Study

Psychedelic Medicine February 3, 2026 Anton T. Gregersen, Tobias P. Whelan, Caroline T. Golden et al. 2 citations

Introduction: Cognitive flexibility is essential for behavioral adaptation in response to environmental changes and is impaired in various neuropsychiatric disorders. The serotonergic psychedelic psilocybin has shown potential in enhancing cognitive flexibility, although with mixed results. In this study, we investigated the effects of psilocybin on cognitive flexibility in rats using a...

DOI: 10.1177/28314425251386879 Psilocybin Serotonergic Touchscreen Cognition +9

Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin

Molecular Psychiatry February 3, 2026 Pablo Mallaroni, S. Parker Singleton, Natasha L. Mason et al.

As psychedelic-assisted psychotherapy gains momentum, clinical investigation of next-generation psychedelics may lead to novel compounds tailored for specific populations. 2,5-dimethoxy-4-bromophenethylamine (2C-B) is a psychedelic phenethylamine reported to produce less dysphoria and subjective impairment than the psychedelic tryptamine psilocybin. Despite its popularity among recreational...

DOI: 10.1038/s41380-026-03447-0 Psilocybin Serotonergic Serotonin Neuroplasticity +13

Stereoselective, sex-dependent 5-HT2A receptor modulation of cortical plasticity by MDMA in mice.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology February 2, 2026 Maya C Gaines-Smith, Justin M Silverman, Michael Fiorillo et al. 3 citations

The psychoactive entactogen 3,4-methylenedioxymethamphetamine (MDMA), widely known as a recreational drug, is gaining renewed attention as a potential psychotherapeutic adjunct for treatment-resistant psychiatric disorders, yet its neurobiological mechanisms - particularly those related to its stereoisomers and sex-specific effects - remain poorly understood. Here, we report stereoselective and...

DOI: 10.1038/s41386-025-02313-x Full text

In Silico Characterization of Bromo-DragonFLY Binding to the 5-HT2A Receptor: Molecular Insights Into a Potent Designer Psychedelic.

Proteins February 1, 2026 Syeda Sumayya Tariq, Urooj Qureshi, Mamona Mushtaq et al.

Bromo-DragonFLY (BDF), a potent designer psychedelic drug with hallucinogenic properties, has recently emerged as a significant recreational substance. Named for its dragonfly-like molecular structure, BDF induces prolonged psychedelic effects, with hallucinations lasting several days. Clinical reports highlight severe toxicity, including confusion, tachycardia, hypertension, seizures, renal...

DOI: 10.1002/prot.70055 Full text Serotonin 5‐ht2a receptor Bromo‐dragonfly Hallucinogen +1

Ayahuasca modulation of traumatic-like fear memories requires infralimbic cortex BDNF-dependent mechanisms in rats.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology February 1, 2026 Isabel Werle, Francisco S Guimarães, Rafael G. Dos Santos et al.

Rodent studies have shown that psychedelic drugs can enhance fear extinction. However, investigations to date have relied on normative aversive conditioning procedures, which limit their relevance to trauma-related memories, as these tend to be overgeneralized and resistant to extinction. Fear extinction depends on activity and plasticity within the infralimbic (IL) region of the medial...

DOI: 10.1016/j.euroneuro.2025.11.009 Full text 5-ht2a receptor Microdosing Neuroplasticity Behavioral flexibility +1

Repeated administration of the synthetic cannabinoid AKB48 induces serotonergic neuroadaptation in male and female mice: behavioural and immunohistochemical evidence.

Neuropharmacology February 1, 2026 Giorgia Corli, Fabrizio De Luca, Sabrine Bilel et al. 1 citation

In the last years, Synthetic Cannabinoids (SCBs) have established themselves as one of the largest and most popular groups of Novel Psychoactive Substances (NPS), being frequently detected in biological samples of patients involved in intoxication and death cases. To date, compelling evidence on the potential interaction between SCBs and non-cannabinoid neurotransmission systems has emerged,...

DOI: 10.1016/j.neuropharm.2025.110758 Full text 25i-nbome pubchem cid 2c-i pubchem cid 5-ht2a receptors Akb48 pubchem cid +5